

Coming of Age of CDK 4-6 inhibitors

Monday 10 October 2016 18.30-20.00
Oslo Auditorium, Bella Center, Copenhagen

Dear colleague,

On behalf of *ecancer*, we are delighted to invite you to a very special educational event that will outline the latest research, data and treatment options for metastatic breast cancer patients.

Attending this highly interactive session will provide clinicians with the latest emerging evidence in the optimal integration of new therapies into treatment plans for breast cancer patients which can be directly applied in clinical practice.

The session will be accredited by the EACCME.

We look forward to seeing you in Copenhagen.

Session Co-Chairs



Dr Giuseppe Curigliano,
Senior Deputy Director,
Division of
Medical Oncology,
European Institute of
Oncology, Milan, Italy



Prof Gordon McVie,
Visiting Professor
in Cancer Studies
at Kings College London,
Founding Editor *ecancer*

Speakers

Pierfranco Conte,
Istituto Oncologico Veneto, Italy

Sara Hurvitz,
Ronald Reagan UCLA Medical Center, USA

Sibylle Loibl,
German Breast Group, Germany

Ghadeer Shubassi,
Institute of Molecular Oncology (IFOM), Italy

Programme

- What are CDKs?
- Existing targeted drugs and their stage of development
- Current indications for CDK 4-6 inhibitors (plus antiestrogen), Biomarkers
- Clinical Trial results, benefits, side effects and costs
- Extending indication of CDK 4-6 inhibitors in the adjuvant and neoadjuvant setting

ecancerevents